Safety and efficacy of moxifloxacin 0.5%/ nepafenac 0.3% ophthalmic suspension for treatment of bacterial conjunctivitis.

Trial Profile

Safety and efficacy of moxifloxacin 0.5%/ nepafenac 0.3% ophthalmic suspension for treatment of bacterial conjunctivitis.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2011

At a glance

  • Drugs Moxifloxacin; Nepafenac
  • Indications Bacterial infections; Conjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Dec 2011 Actual patient number is 0 according to ClinicalTrials.gov.
    • 30 Dec 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 16 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top